CAR-T Therapy has shown an unprecedented success in the treatment of Hematological Tumors. In order to develop an Universal CAR-T based in own technology, Canvax Biotech has executed the project «Dymorphic and Universal CAR-T for Cancer Immunotherapy, Infectious and Autoimmune Diseases». This project has been co-funded by CDTI and Fondo Europeo de Desarrollo Regional (FEDER) […]
Learn More
FRIDASTEM platform has been established with the aim to accelerate small molecule drug discovery against specific kinases and GPCRs involved in Cancer Stem Cells (CSC) proliferation, migration, invasion or metastasis. CSC are believed to be the cause of resistance to current cancer therapies. The drug discovery of drugs targeting this population of cells within a tumoris therefore of […]
Learn More
Canvax Biotech has recently received an endorsement from the Ministry of Economy and Competitiveness (MINECO) through the RETOS-COLABORACIÓN Program. Canvax Biotech will lead the consortium composed by Villapharma Research from Murcia, Instituto de Investigación Biomédica of Bellvitge (IDIBELL), two scientific groups from Instituto de Investigación Biomédica of Córdoba (IMIBIC) and two groups from Universidad de […]
Learn More
Canvax has been recently reinforced its Drug Discovery program by the incorporation of PhD Emilio González González, who was awarded with a Torres Quevedo contract from MINECO (PTQ 2014). He is an experienced scientist-entrepreneur who received his PhD at Complutense University and Centro de Investigaciones Biológicas and received a postdoctoral/biotech education at Stanford University/Transderm and […]
Learn More
Canvax Biotech’s odour-GPCR-based diagnostics technology is one of the few excellent projects awardees of the highly competitive H2020. For more information, read the attached pdf with all awardees here.
Learn More
Canvax Biotech has hosted in its headquarters the last Technical Committee of the SNC-Integra project, developed by a biotechnology cluster of Andalusian companies, led by Laboratorios Rovi and where, together with Canvax Biotech,there are participating companies such as VivaCell, Bionaturis, GMV, Vivia Allosterics and Vivia Biotech. This technical committee presented the main conclusions of this […]
Learn More
Canvax Biotech has been a beneficiary of ‘Invest in Spain’ funds from ICEX, that aims to help these companies with foreign participation to develop R&D projects in Spain. The project is based on FRIDA, a cell sensor developed by Canvax, for functional screening of the activity of compounds against the GPCRs to find news drugs […]
Learn More
The Oncology Consortium, composed of seven Spanish biotech companies and led by PharmaMar, has generated since its launch four years ago, a total of 9 patent applications, 5 papers and 13 posters at international conferences, plus three doctoral theses and 12 scientific publications Together with Canvax and PharmaMar, the other companies involved in the consortium […]
Learn More